MULTIPLE MYELOMA (MM)

This study tests whether a combination of two drugs (elranatamab and daratumumab) can work as well as or better than a stem cell transplant for people newly diagnosed with multiple myeloma. About 100 adults who have already had initial treatment will be randomly assigned to one o…

This study tests if a new drug, HLX15-SC, works as well as the approved drug DARZALEX FASPRO® for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 258 adults will receive either the new drug or the approved one, along with standard medica…

This phase 2 trial is testing a combination of two drugs—CM336 (a bispecific antibody) and isatuximab (a monoclonal antibody)—in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function…

This study tests whether raising blood levels of a natural molecule called beta-hydroxybutyrate (BHB) — through a strict ketogenic diet or ketone drinks — is safe and can improve the effectiveness of immunotherapy (CAR-T cells or bispecific antibodies) in 45 adults with multiple …

This early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers…

This study tests two drug combinations (teclistamab plus daratumumab or talquetamab plus daratumumab) in 150 frail patients newly diagnosed with multiple myeloma. The goal is to see if these fixed-duration treatments can control the cancer for at least 18 months. Participants rec…

This phase 3 trial is testing whether adding an experimental drug called SCTC21C to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The study will en…

This early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…

This study is testing whether a 6-month, personalized exercise program can improve the quality of life for people with multiple myeloma. The program mixes in-person sessions at the hospital with at-home workouts. Researchers will compare participants who get the exercise program …

This study looks at people with early blood disorders (MGUS and smoldering myeloma) who are at risk of developing multiple myeloma, a type of bone marrow cancer. Researchers will use advanced genetic and immune testing on blood and bone marrow samples, along with mouth bacteria a…

This study looks at 60 multiple myeloma patients who are about to receive CAR-T cell therapy. Researchers will measure a specific immune marker (TCF-1) in the blood before treatment and track how long the modified CAR-T cells last afterward. The goal is to find clues that predict…